Boston Biomedical Innovation Center

波士顿生物医学创新中心

• 批准号: 8916925
• 负责人: DAVID E. GOLAN
• 金额: $ 111.85万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8916925
• 关键词: Academia; Achievement; Address; Biological Sciences; Biomedical Technology; Blood; Boston; Cardiovascular system; Clinical; Commit; Communities; Decision Making; Development; Devices; Diagnostic; Elements; Ensure; Environment; Funding; Goals; Government Agencies; Healthcare; Heart; Heart Diseases; Hematological Disease; Hematology; Individual; Institution; Knowledge; Lung; Lung diseases; Medical; Medicine; Mentors; Mission; National Heart, Lung, and Blood Institute; Patients; Private Sector; Process; Public Sector; Rare Diseases; Research Infrastructure; Research Personnel; Resources; Rewards; Secure; Seeds; Sleep; Sleep Disorders; Societies; Speed; Staging; Technology; Therapeutic; Time; Translational Research; Translations; clinical application; clinical practice; commercialization; experience; innovation; meetings; new technology; public-private partnership; skills; success; tool; validation studies

A well-recognized gap exists in the path from biomedical discovery in academia to clinical application and commercialization of therapeutic, device, and diagnostic technologies in cardiovascular, pulmonary, hematologic, and sleep disorders. This chasm is the result of inadequate funding for support of proof-of-concept or validation studies essential for early stage development; insufficient access to the resources and expertise needed to develop new technologies; and a lack of knowledge and experience among academic investigators in bringing new ideas to commercial realization. Within the partnering institutions included in this application, the essential elements exist with which to build the infrastructure needed to support and sustain the uninterrupted, durable flow of inventions from discovery through development and commercialization. While these institutions have a clear track record of remarkably successful development of many biomedical technologies, most of these commercial successes have been achieved by the tenacity of individual inventors rather than with the help of committed institutional mechanisms. We proposed to address these key shortcomings by establishing the regional Boston Center for Accelerated Innovation in Therapeutics, Devices, and Diagnostics for Heart, Lung, Blood, and Sleep Disorders (B-BIC, or the Boston Biomedical Innovation Center). The key objectives of this Center are to: 1) develop an integrated infrastructure that would expand the universe of commercializable technologies for heart, lung, blood, and sleep disorders; 2) place these opportunities in the proper evaluative context through an engagement ("seed it"), solicitation ("find it"), and selection ("pick it") strategy; 3) efficiently and effectively bring those selected to an appropriate exit point from the development process; and 4) provide the educational and mentoring infrastructure necessary for the development of the proper entrepreneurial skills among academic innovators. By achieving these goals, B-BlC would change the culture of our academic environment, as well as the relationship between the public and private sectors in facilitating successful development strategies for technologies in heart, lung, blood, and sleep disorders for the ultimate benefit of patients and society.

从学术界的生物医学发现到临床应用和 心血管，肺部的治疗，装置和诊断技术的商业化 血液学和睡眠障碍。这种鸿沟是支持概念证明的资金不足的结果 或验证研究对于早期发展至关重要；无法访问资源和 开发新技术所需的专业知识；并且缺乏学术的知识和经验 调查人员将新想法带入商业实现。在包括的合作机构中 此应用程序，存在建立支持和支持基础架构的基本要素 维持从发现到开发和 商业化。尽管这些机构有明确的发展记录 在许多生物医学技术中，大多数这些商业成功都是通过坚韧的 单个发明者，而不是借助坚定的机构机制。我们提出了 通过建立波士顿地区加速创新中心来解决这些关键缺点 心脏，肺，血液和睡眠障碍（B-BIC或波士顿）的治疗疗法，设备和诊断 生物医学创新中心）。该中心的关键目标是：1）开发一个集成的 将扩大心脏，肺，血液和可扩展商业化技术宇宙的基础设施 睡眠障碍； 2）通过参与将这些机会放在适当的评估环境中（“种子） IT”），招标（“找到”），选择（“选择”）策略; 3） 开发过程的适当出口； 4）提供教育和指导 在学术中发展适当的企业家技能所需的基础设施 创新者。通过实现这些目标，B-Blc将改变我们学术环境的文化，因为 以及公共部门与私营部门之间的关系，以促进成功发展 心脏，肺，血液和睡眠障碍的技术策略，以使患者和社会的最终益处。